Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, announced the first patient has been dosed with imlifidase in the GOOD-IDES-02 trial, a global pivotal phase 3 trial in anti-glomerular basement membrane disease.
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, announced the first patient has been dosed with imlifidase in the GOOD-IDES-02 trial, a global pivotal phase 3 trial in anti-glomerular basement membrane disease.